DOP2013000236A - Inhibidores de la poli(adp-ribosa)polimerasa(parp) para el tratamiento de la neuropatia periferica inducida por quimioterapia (cipn) - Google Patents

Inhibidores de la poli(adp-ribosa)polimerasa(parp) para el tratamiento de la neuropatia periferica inducida por quimioterapia (cipn)

Info

Publication number
DOP2013000236A
DOP2013000236A DO2013000236A DO2013000236A DOP2013000236A DO P2013000236 A DOP2013000236 A DO P2013000236A DO 2013000236 A DO2013000236 A DO 2013000236A DO 2013000236 A DO2013000236 A DO 2013000236A DO P2013000236 A DOP2013000236 A DO P2013000236A
Authority
DO
Dominican Republic
Prior art keywords
parp
adp
chemotherapy
polymerase
treatment
Prior art date
Application number
DO2013000236A
Other languages
English (en)
Inventor
Vincent Louis Giranda
Alexander R Shoemaker
Kaitlin E Browman
Shailen K Joshi
Jill-Desiree Brederson
Thomas D Penning
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45976523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000236(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of DOP2013000236A publication Critical patent/DOP2013000236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de un inhibidor de Ia poIi(ADP-ribosa)polimerasa (PARP) para Ia preparacion de un medicamento para el tratamiento de Ia neuropatla inducida por quimioterapia, en un sujeto que lo necesita.
DO2013000236A 2011-04-11 2013-10-10 Inhibidores de la poli(adp-ribosa)polimerasa(parp) para el tratamiento de la neuropatia periferica inducida por quimioterapia (cipn) DOP2013000236A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473970P 2011-04-11 2011-04-11
US201161476616P 2011-04-18 2011-04-18

Publications (1)

Publication Number Publication Date
DOP2013000236A true DOP2013000236A (es) 2014-01-15

Family

ID=45976523

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000236A DOP2013000236A (es) 2011-04-11 2013-10-10 Inhibidores de la poli(adp-ribosa)polimerasa(parp) para el tratamiento de la neuropatia periferica inducida por quimioterapia (cipn)

Country Status (17)

Country Link
US (2) US20120258180A1 (es)
EP (1) EP2696870A1 (es)
JP (1) JP2014510787A (es)
CN (1) CN103687597A (es)
AR (1) AR085976A1 (es)
AU (1) AU2012243132A1 (es)
BR (1) BR112013026327A2 (es)
CA (1) CA2832817A1 (es)
CL (1) CL2013002908A1 (es)
DO (1) DOP2013000236A (es)
IL (1) IL228719A0 (es)
MX (1) MX2013011932A (es)
NZ (1) NZ616227A (es)
RU (1) RU2013150102A (es)
SG (2) SG2014014294A (es)
TW (1) TW201244714A (es)
WO (1) WO2012141990A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
US20160151339A1 (en) * 2013-03-21 2016-06-02 Hossein A. Ghanbari Treatment for Chemotherapy-Induced Peripheral Neuropathy
US20140287021A1 (en) * 2013-03-21 2014-09-25 Panacea Pharmaceuticals Treatment of chemotherapy-induced peripheral neuropathy
EP3325623B3 (en) 2015-07-23 2021-01-20 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018181860A1 (ja) * 2017-03-31 2018-10-04 東レ株式会社 末梢神経障害の治療剤又は予防剤
EP3765613A1 (en) 2018-03-13 2021-01-20 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
KR20210088632A (ko) * 2018-11-08 2021-07-14 인8바이오 인코포레이티드 암의 치료용 조성물 및 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
ES2981848T3 (es) * 2020-09-22 2024-10-10 Anilur Pharma S L C-ficocianina para usar en el tratamiento y/o la prevención de la neuropatía periférica

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006206512B2 (en) * 2005-01-19 2012-09-13 Eisai Inc. Diazabenzo(de)anthracen-3-one compounds and methods for inhibiting PARP
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2007084532A2 (en) 2006-01-17 2007-07-26 Abbott Laboratories Combination therapy with parp inhibitors
MY165570A (en) 2006-12-28 2018-04-05 Abbvie Inc Inhibitors of poly (adp-ribose) polymerase
DK2209375T3 (da) * 2007-10-03 2014-10-06 Eisai Inc Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
EP2727921B1 (en) * 2007-10-12 2017-04-19 AbbVie Ireland Unlimited Company 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 2

Also Published As

Publication number Publication date
SG2014014294A (en) 2014-06-27
EP2696870A1 (en) 2014-02-19
US20120258180A1 (en) 2012-10-11
JP2014510787A (ja) 2014-05-01
AR085976A1 (es) 2013-11-06
AU2012243132A1 (en) 2013-10-24
CA2832817A1 (en) 2012-10-18
BR112013026327A2 (pt) 2019-09-24
CL2013002908A1 (es) 2013-12-06
SG194138A1 (en) 2013-11-29
IL228719A0 (en) 2013-12-31
TW201244714A (en) 2012-11-16
US20140093585A1 (en) 2014-04-03
NZ616227A (en) 2016-01-29
WO2012141990A1 (en) 2012-10-18
MX2013011932A (es) 2013-11-01
RU2013150102A (ru) 2015-05-20
CN103687597A (zh) 2014-03-26

Similar Documents

Publication Publication Date Title
DOP2013000236A (es) Inhibidores de la poli(adp-ribosa)polimerasa(parp) para el tratamiento de la neuropatia periferica inducida por quimioterapia (cipn)
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
DOP2015000098A (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2014002589A1 (es) Compuestos inhibidores de beta-lactamasas derivados de 7-oxo-1,6-diazabiciclo[3.2.1] octano; composicion farmaceutica que los comprende y uso para tratar una infeccion bacteriana.
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2014002915A1 (es) Compuestos derivados de imidazotiadiazol e imidazopirazina, como inhibidores del receptor activado de proteasa 4 (par4); composicion farmaceutica que los comprende; y su uso para inhibir o prevenir la agregacion plaquetaria y por lo tanto utiles en el tratamiento de un trastorno tromboembolico o para la profilaxis primaria o secundaria de un trastorno tromboembolico.
CR20150326A (es) Inhibidores de autotaxina
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
UY34264A (es) Compuestos de fórmula genérica 4-(8-metoxi-1-(1-metoxipropan-2-il)-2-(tetrahidro-2H-piran-4-il)-1H- imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y sus sales.
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
BR112013028422A2 (pt) ativadores de piruvato cinase para uso em terapia
EA201400178A1 (ru) Лечение рака молочной железы
CL2015000294A1 (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
CR20110622A (es) Conjunto de aguja para dispositivo para biopsias
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
AR089336A1 (es) Composiciones para el cuidado oral